← All trials
NCT06033950
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2024
- Primary completion
- Jun 30, 2026
- Completion date
- Nov 30, 2027
- First posted
- Sep 13, 2023
- Last posted
- Sep 21, 2023
- Enrollment
- 2600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Colorado Prevention CenterLead sponsor
- BayerCollaborator
- Saint Luke's Health SystemCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.